Lirilumab, a novel immunotherapeutic antibody targeting LAG-3, represents a notable advance in cancer treatment. Its development began with early investigations demonstrating LAG-3's role in disease progression. https://lirilumab-anti-kir-antib193092.wikipublicity.com/user